Directed Finance operations with 2 direct / 3 indirect reports and $18M budget. Planned and implemented strategic vision and objectives in addition to short and long-term objectives for organization. Managed all financial functions including monthly financial statements and summaries. Monitored cash flows, budgets, forecasts, variance analysis, project costs, and policies. Recommended strategies to leadership including cost reductions and efficiency improvements to increase financial health of company. Negotiated Confidential Disclosure (CDA) and Master services Agreements (MSA) with clients in conjunction with Corporate Counsel and Senior Vice President of Strategic Development. Built and fostered productive relationships with clients and vendors representing Finance and HR departments. Key player in Federal and State tax planning for CEO / Founder and company. Completed special projects and maintained current knowledge of Pharmaceutical standards and industry trends.* Drove focus on Accounts Receivable management and reduced DSO by 12 days.* Reduced Client Billing Cycle process by 22% to improve timelines of billing. Managed Debt consolidation to improve Balance Sheet condition. Executive sponsor of SAP Business One ERP implementation. * Collaborated with President / CEO and executive leadership to develop financial and human resource goals and objectives increasing organizational profitability 20% and reducing costs 5%.* Partnered with Private Banking group to evaluate possible strategic transactions for Company.

Direct R&D Finance operations with $100M budget and transaction approval authority up to $5M. Manage three direct reports including Senior Manager, and two Senior Business Analysts. Ensure successful completion of monthly financial close. Develop internal budget and manage forecasting process as business partner for Waltham R&D site management. Support Medical Affairs group within Genzyme R&D function. Monitor compliance with corporate financial policies, external/internal audit requirements, and Sarbanes-Oxley (SOX). Participate on Transparency Task Force managing compliance with State and Federal disclosure laws regarding payments to Medical Care Providers under the Sunshine Act.* Collected 1.8M Euros from Austrian VAT authority owed for two years. * Managed financial impact of $35M large scale clinical trial. Supported Clinical Development group and Renal Business unit requiring significant interaction with vendor and Clinical Purchasing team.* Key player in integration of Bone Care International acquisition. Ensured compliance of remote site personnel with corporate financial policies and reporting process.* Allocated Waltham site capital budget to ensure overall capital needs are met in an equitable manner.* Participated within two M&A integrations driving productivity, profitability, and operations efficiency.

Ensured successful cash management, accounting, financial reporting, budgeting/planning, payroll administration, and risk management in addition to IT, Facilities, and HR operations management with full P&L accountability. Served as key member of lead product CE Mark team. Recommended business development and strategic options for liquidity exit to CEO and BOD. Reported to Founder and CEO.* Launched product in Europe in 25 months from development to clinical trials and CE Mark approval.* Selected, built-out, and relocated operations from Boston location of 300 sq. ft. to 9,500 sq. ft. in Waltham - completed project on time and under budget.* Initiated performance incentives and bonus program. Implemented cost effective and competitive benefits portfolio. Negotiated and set up outsourcing contract with European third party logistics firm.* Negotiated and selected strategic R&D manufacturing partners focusing on maintaining acceptable COGS and margins.

Led financial and administrative operations within R&D stage company managing cash management, accounting, financial reporting, budgeting, planning, payroll, risk, facilities, HR, and benefits. Analyzed corporate collaboration with large pharmaceutical company for suitability. Communicated extensively with Investor Relations and managed intellectual property issues. Attended and presented at BOD meetings. Collaborated with and reported to CEO. Assessed exit strategies for company and positioned for profitable sale to Genzyme.

Recruited post recent IPO with organization in challenging financial position. Managed daily financial operations and conducted internal analyses to improve profitability, efficiency, and cost control. Collaborated with functional VPs to balance operational needs with limited financial resources. Maintained general ledger, payroll, AP/AR, sales order processing, and fixed assets. Maximized use of cash by negotiating payment plans with vendors. Collected 100% of money owed by CIA via collaboration with local Congressman.

Managed worldwide controller operations including tax, payroll, SEC reporting, and annual audit process with P&L accountability for capital and operating budgets. Upgraded IT systems and led implementation of new general ledger package ensuring effectiveness of innovative paperless purchasing system. Key player in successful IPO in 1994 and follow-on offering in February 1996 – company managed private placement in May 1996. Saved 40% in Sales Tax and Use Tax in Massachusetts by challenging audit decision and winning in appeals process.